Related Experiment Video
Updated: Dec 31, 2025
06:51
Cefoperazone-treated Mouse Model of Clinically-relevant Clostridium difficile Strain R20291
Published on: December 10, 2016
13.1K
Ceftriaxone-Induced Hemolytic Anemia: A Rare Case Report
Sandeep Kumar1, Rohit Bansal2, Priya Bansal1
1Department of Medicine, Lady Hardinge Medical College, New Delhi, India.
The Permanente Journal
|January 7, 2020
Summary
Drug-induced immune hemolytic anemia (DIIHA) is a rare but potentially fatal complication of medications. Early recognition and prompt cessation of the offending drug, such as ceftriaxone, are crucial for patient survival, even with negative diagnostic tests.
Area of Science:
- Hematology
- Immunology
- Pharmacology
Background:
- Drug-induced immune hemolytic anemia (DIIHA) is a rare, potentially fatal complication of drug therapy.
- It is often underdiagnosed, necessitating high clinical suspicion.
- Ceftriaxone is a frequent cause of DIIHA.
Observation:
- A case of ceftriaxone-induced immune hemolytic anemia is presented in a 62-year-old woman.
- The patient exhibited a negative direct antiglobulin test (DAT).
Findings:
- Ceftriaxone is associated with severe outcomes in DIIHA.
- Negative DAT results do not exclude DIIHA.
- Prompt drug cessation is vital for managing DIIHA.
Implications:
- Clinicians must maintain a high index of suspicion for DIIHA in relevant settings.
- Investigate potential culprit drugs meticulously, especially when hemolysis is unclear and DAT is negative.
- Timely discontinuation of implicated drugs is essential to prevent severe complications and fatalities.
